Evidence map›Paper›PMID 32033040›Full record

ArticleAntioxidants (Basel, Switzerland)2020

Cannabidiol Protects Dopaminergic Neurons in Mesencephalic Cultures against the Complex I Inhibitor Rotenone Via Modulation of Heme Oxygenase Activity and Bilirubin.

Johanna Catharina Duvigneau, Alice Trovato, Andrea Müllebner, Ingrid Miller, Christopher Krewenka, Kristina Krenn, Wilhelm Zich, Rudolf Moldzio

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Johanna Catharina DuvigneauInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Alice TrovatoInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Andrea MüllebnerInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Ingrid MillerInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Christopher KrewenkaInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Kristina KrennInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Wilhelm ZichInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
Rudolf MoldzioInstitute of Medical Biochemistry, University of Veterinary Medicine Vienna, Veterinaerplatz 1, 1210 Vienna, Austria.
University of Veterinary Medicine Vienna · AT

Funding

Herzfelder´sche Familienstiftung, Vienna, Austria 16022015
6 · The paper itself

Abstract

Phytocannabinoids protect neurons against stressful conditions, possibly via the heme oxygenase (HO) system. In cultures of primary mesencephalic neurons and neuroblastoma cells, we determined the capability of cannabidiol (CBD) and tetrahydrocannabinol (THC) to counteract effects elicited by complex I-inhibitor rotenone by analyzing neuron viability, morphology, gene expression of IL6, CHOP, XBP1, HO-1 (stress response), and HO-2, and in vitro HO activity. Incubation with rotenone led to a moderate stress response but massive degeneration of dopaminergic neurons (DN) in primary mesencephalic cultures. Both phytocannabinoids inhibited in-vitro HO activity, with CBD being more potent. Inhibition of the enzyme reaction was not restricted to neuronal cells and occurred in a non-competitive manner. Although CBD itself decreased viability of the DNs (from 100% to 78%), in combination with rotenone, it moderately increased survival from 28.6% to 42.4%. When the heme degradation product bilirubin (BR) was added together with CBD, rotenone-mediated degeneration of DN was completely abolished, resulting in approximately the number of DN determined with CBD alone (77.5%). Using N18TG2 neuroblastoma cells, we explored the neuroprotective mechanism underlying the combined action of CBD and BR. CBD triggered the expression of HO-1 and other cell stress markers. Co-treatment with rotenone resulted in the super-induction of HO-1 and an increased in-vitro HO-activity. Co-application of BR completely mitigated the rotenone-induced stress response. Our findings indicate that CBD induces HO-1 and increases the cellular capacity to convert heme when stressful conditions are met. Our data further suggest that CBD via HO may confer full protection against (oxidative) stress when endogenous levels of BR are sufficiently high.

Indexed as

bilirubin: rotenonebiliverdin reductaseheme oxygenaseneuroprotectionphytocannabinoids

Identifiers

PMID32033040
PMCPMC7070382
OpenAlexW3004976066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.